Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Koch

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Muscle & Nerve|June 2, 2025
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular DystrophyJoanne Donovan, Jeffrey A Silverman, Ben Barthel, et al.
Journal of Medicinal Chemistry|January 20, 2006
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-onesEli M Wallace, Joseph Lyssikatos, James F Blake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitorTammie C Yeh, Vivienne Marsh, Bryan A Bernat, et al.
The Journal of Clinical Investigation|March 30, 2023
Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophyAlan J Russell, Mike DuVall, Ben Barthel, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Muscle & Nerve|June 2, 2025
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular DystrophyJoanne Donovan, Jeffrey A Silverman, Ben Barthel, et al.
Journal of Medicinal Chemistry|January 20, 2006
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-onesEli M Wallace, Joseph Lyssikatos, James F Blake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitorTammie C Yeh, Vivienne Marsh, Bryan A Bernat, et al.
The Journal of Clinical Investigation|March 30, 2023
Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophyAlan J Russell, Mike DuVall, Ben Barthel, et al.
Pageof 3